<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711382</url>
  </required_header>
  <id_info>
    <org_study_id>Fiasp real-world data</org_study_id>
    <nct_id>NCT04711382</nct_id>
  </id_info>
  <brief_title>The Use of Faster Acting Aspart in Type 1 Diabetes Patients</brief_title>
  <official_title>The Use of Faster Acting Aspart in Type 1 Diabetes Patients: Multi-centre Real-world Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in&#xD;
      routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of&#xD;
      switching from traditional mealtime insulin to Fiasp in a &quot;real-world&quot; clinical practice&#xD;
      setting in people with type 1 diabetes in Belgium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12&#xD;
      months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range&#xD;
      (T&lt;70 and T&lt;54 mg/dl) and time above range (T&gt;180 and T&gt;250 mg/dl).&#xD;
&#xD;
      Retrospective analysis Two-center study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time in Range</measure>
    <time_frame>12 months</time_frame>
    <description>Time in target range at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in Range</measure>
    <time_frame>6 months</time_frame>
    <description>Time in target range at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
    <description>Change in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin doses</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
    <description>Change in insulin doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
    <description>Change in time below range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above range</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
    <description>Change in time above range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
    <description>Change in coefficient of variation</description>
  </secondary_outcome>
  <enrollment type="Actual">438</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Insulin</condition>
  <condition>Time in Range</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult type 1 diabetes patients, with a duration of diabetes of &gt; 2 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes patients&#xD;
&#xD;
          -  Duration of diabetes &gt; 2 years&#xD;
&#xD;
          -  Using CGM for &gt; 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Using SMBG&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Using glucocorticoids or immunosuppressive agents&#xD;
&#xD;
          -  Active oncological problem&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fast acting insulin</keyword>
  <keyword>glucometrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

